Showing 921-930 of 18562 results for "".
New Insights in the Management of HCM: Exploring the Clinical Spectrum
https://reachmd.com/programs/cme/new-insights-in-the-management-of-hcm-exploring-the-clinical-spectrum/33026/Explore personalized strategies in obstructive HCM, from diagnosis to treatment evolution, including real-world insights into cardiac myosin inhibitor use.NYHA FC and Finerenone Response: Clinical Trial Insights
https://reachmd.com/clinical-practice/cardiology/nyha-fc-and-finerenone-response-clinical-trial-insights/33215/Dr. Ostrominski discusses new data from ACC 2025 showing that finerenone improves patient outcomes in HFmrEF/HFpEF, regardless of baseline NYHA class.Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
https://reachmd.com/programs/cme/innovative-approaches-to-managing-ckm-syndrome-and-hfmrefhfpef/29912/CKM syndrome and HFmrEF/HFpEF present a rising global burden. Tune in to explore emerging therapies with a proven impact on outcomes.CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
https://reachmd.com/clinical-practice/cardiology/cetp-inhibition-with-obicetrapib-implications-for-cardiovascular-event-prevention/37124/CETP Inhibition with Obicetrapib: Implications for Cardiovascular Event PreventionAPOC3 Inhibition: New Frontiers Managing Patients with FCS & SHTG
https://reachmd.com/programs/cme/apoc3-inhibition-new-frontiers-managing-patients-with-fcs-shtg/20307/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.When Topicals Fail: The New IPC Consensus Every Clinician Should Know
https://reachmd.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/Review IPC’s 2025 consensus guidance on reclassifying psoriasis severity and redefining failure of topical therapies.IgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
https://reachmd.com/programs/cme/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/Examine updated KDIGO 2025 IgAN guidelines and the new approach to managing proteinuria and slowing kidney function decline.CETP Inhibition and Obicetrapib: A New Era in Lipid Management
https://reachmd.com/clinical-practice/cardiology/cetp-inhibition-and-obicetrapib-a-new-era-in-lipid-management/37123/CETP Inhibition and Obicetrapib: A New Era in Lipid ManagementCrossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
https://reachmd.com/programs/cme/crossing-boundaries-cetp-inhibitors-and-the-next-frontier-in-lipid-control/33025/Exploring CETP inhibition as the next breakthrough in lipid lowering, cardiologists highlight mechanisms, trials, and its role as a future CV therapy.APOC3 Inhibition: A Novel Approach to Lowering TGs
https://reachmd.com/programs/cme/apoc3-inhibition-a-novel-approach-to-lowering-tgs/33222/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.